Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PCSS who wrote (1669)	7/1/2003 12:17:00 AM
From: Miljenko Zuanic	Read Replies (3) of 3044

<< MLNM retained all commercial rights for Velcade in the US (which represents 60-70% of the global potential).>> This is very wrong. Today US economic is ~40-50% of worldwide, but it may (and will) change dramatically in coming years. Global market has significant potential, imo. << Furthermore, JNJ's financial support and expertise may accelerate the development of Velcade for new indications, including non-Hodgkin's lymphoma (NHL) and solid tumors.>> What are J&J oncology expertise? Selling supportive care medicine? In this deal MLNM is taking significant risk, but with even greater reward down the road. The key to success is Velcade success is multiple cancer indications, superiority in efficacy/safety relative to competitors, and easiest to market drug (predictive medicine). To retain full US market there is not too many options available. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next